文献速递白血病MDS 与骨髓增殖性肿瘤

去甲基化药物治疗急性髓系白血病与骨髓增生异常综合征:耐药机制及新型联合策略

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
PubMed 文献 · Leukemia · 2021-05-06

该综述聚焦去甲基化药物(HMA)治疗急性髓系白血病和骨髓增生异常综合征的作用机制、耐药产生及克服策略。第一代HMA阿扎胞苷与地西他滨已用于标准临床,尤其适合老年、医学上不适合强化疗的患者,但耐药几乎不可避免。文章汇总下一代HMA及以HMA为基础的联合治疗等克服耐药的策略。

要点

  • HMA通过逆转DNA异常甲基化重编程肿瘤细胞,用于AML和MDS。
  • 第一代HMA阿扎胞苷和地西他滨尤其适用于老年、不适合强化疗患者。
  • 随用药时间延长耐药几乎不可避免,需下一代HMA及联合治疗策略。

核心结论

  • HMA耐药是长期治疗中几乎不可避免的问题,下一代HMA与HMA为基础联合治疗是克服耐药的主要方向。

研究设计与样本

  • 综述类文章,汇总HMA作用机制、耐药机制及克服耐药策略,未报告具体检索范围与样本量。

主要发现

  • 异常DNA甲基化在肿瘤发生与进展中起关键作用。
  • 第一代HMA阿扎胞苷和地西他滨可逆转DNA甲基化并重编程肿瘤细胞。
  • 随HMA使用时间延长,几乎不可避免地出现耐药。

临床怎么用

  • 第一代HMA阿扎胞苷和地西他滨已作为AML和MDS标准临床用药,尤其用于老年、医学上不适合强化疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The first-generation HMA azacitidine and decitabine have now been in standard clinical use for some time, offering a valuable alternative to previous treatments in acute myeloid leukemia and myelodysplastic syndromes, so far particularly in older, medically non-fit patients. However, the longer we use these drugs, the more we are confronted with the (almost inevitable) development of resistance. This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021. PMID: 33958699. doi:10.1038/s41375-021-01218-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。